A detailed history of Ameriprise Financial Inc transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Ameriprise Financial Inc holds 24,058 shares of KYMR stock, worth $1.56 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24,058
Previous 19,533 23.17%
Holding current value
$1.56 Million
Previous $852,000 59.74%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$37.68 - $58.5 $170,502 - $264,712
4,525 Added 23.17%
24,058 $1.36 Million
Q2 2025

Aug 14, 2025

BUY
$21.05 - $48.6 $87,546 - $202,127
4,159 Added 27.05%
19,533 $852,000
Q1 2025

May 14, 2025

BUY
$27.37 - $44.36 $186,937 - $302,978
6,830 Added 79.94%
15,374 $420,000
Q4 2024

Feb 14, 2025

BUY
$39.06 - $51.84 $333,728 - $442,920
8,544 New
8,544 $343,000
Q1 2023

May 15, 2023

BUY
$24.84 - $38.75 $185,554 - $289,462
7,470 New
7,470 $221,000

Others Institutions Holding KYMR

About Kymera Therapeutics, Inc.


  • Ticker KYMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,705,800
  • Market Cap $3.55B
  • Description
  • Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...
More about KYMR
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.